drugset / Trial / NCT04626063

Magnesium Oral Supplementation for Acute Non-specific Low Back Pain

NCT04626063

Completed 240 enrolled Istanbul University
RandomizedParallel-groupOpen-labelTreatment

Summary

Acute non-specific low back pain (LBP) is one of the most common complaints at the emergency department. It is more prevalent in countries with high-income economies, where 60-80% of the population report back pain at some point in their life. Numerous medication options are available for acute LBP relief such as non-steroid anti-inflammatory drugs (NSAIDs), myorelaxant drugs, opioids, and benzodiazepines. Magnesium is a physiological voltage-dependent blocker of N-methyl-D-aspartate NMDA)-coupled channels that can influence inflammatory pain and neuropathic pain through several different mechanisms. In this study the investigators aimed to investigate the effect of magnesium oral supplementation for acute low back pain.

Timeline

Start
2018-06-10
Primary completion
2019-03-15
Completion
2020-03-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule 500 mg
Subject Magnesium Sulfate Other / unclassified 365 mg Oral
Comparator Etodolac Unknown 400 mg

Indications

No indication recorded.